Immunotherapy against EBV-lymphoma in recipients of HSCT

Research output: Contribution to journalArticlepeer-review


Epstein-Barr virus (EBV)-associated lymphoproliferations represent life-threatening complications of hematopoietic stem cell transplantation. In the last decade, immunological therapeutic strategies that allow us to selectively abrogate the origin of lymphoproliferation, namely B-cell compartment or EBV antigen-expressing tumor cells, have significantly reduced treatment-related toxicity while maintaining equal or superior efficacy. A further implementation is the possibility of preventing disease occurrence by delivering immunotherapy in the presymptomatic phase, on the basis of EBV-DNA blood levels. Despite the excellent results, T-cell therapy with EBV-specific cytotoxic T-lymphocytes has but a marginal role in the treatment of these forms. Promising implementations are underway, including logistic solutions to extend T-cell therapy beyond academic centers, delineation of strategies aimed at simplifying/shortening production and targeting immune evasion mechanisms exerted by tumor cells.

Original languageEnglish
Pages (from-to)625-632
Number of pages8
JournalExpert Review of Hematology
Issue number5
Publication statusPublished - Oct 2010


  • allogeneic stem cell transplantation
  • Epstein-Barr virus
  • lymphoproliferative disease
  • minimization of treatment-related toxicity
  • monoclonal antibody therapy
  • T-cell therapy

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Immunotherapy against EBV-lymphoma in recipients of HSCT'. Together they form a unique fingerprint.

Cite this